More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$2.17B
EPS
-0.66
P/E ratio
--
Price to sales
17.01
Dividend yield
--
Beta
2.229875
Previous close
$22.83
Today's open
$22.41
Day's range
$20.65 - $22.70
52 week range
$20.23 - $38.26
show more
CEO
John Evans
Employees
511
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
103495644
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Beam Therapeutics Inc. (BEAM) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
Seeking Alpha • 5 hours ago

Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up
Beam Therapeutics receives a Buy rating, driven by promising data across AATD, GSDIa, and SCD, and robust funding. BEAM's risto-cel SCD therapy shows strong efficacy but faces market skepticism due to challenging treatment regimens and competition. The company's in-vivo gene editing pipeline, especially BEAM-302 in AATD, is viewed as the primary value driver amid industry doubts.
Seeking Alpha • Nov 12, 2026

BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.
Zacks Investment Research • Nov 11, 2026

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
Bears are crowding into a small group of stocks, and one name has nearly its entire float sold short.
Benzinga • Nov 11, 2026

Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary Safety Endpoints at the Prespecified Interim Analysis Study Met All Secondary Endpoints Including Freedom from Inpatient Hospitalization for Severe VOCs for 12 Consecutive Months Results Support Planned U.S. Biologics License Application (BLA) Submission for risto-cel, Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced positive topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).
GlobeNewsWire • Nov 10, 2026

Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans.
GlobeNewsWire • Nov 4, 2026

Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027
GlobeNewsWire • Nov 3, 2026

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.
Zacks Investment Research • Nov 3, 2026

3 Promising Genomics Stocks to Add to Your Portfolio Now
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Zacks Investment Research • Oct 30, 2026

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?
Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Beam Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.